Company intelligence / Profile preview

Shanghai Juntuo Biosciences

Ownership: Private
Employees: ~2500
Development stage: Other

Overview

The company has multiple approved products including toripalimab (China's first domestically produced anti-PD-1 monoclonal antibody, approved in over 35 countries including the US and Europe), adalimumab biosimilar, and deuremidevir hydrobromide. In 2024, toripalimab domestic sales revenue was approximately RMB1,501 million, representing a 66% increase compared to 2023.

Therapeutic areas: OncologyMetabolic DisordersImmunologyDermatologyRheumatologyGastroenterologyOphthalmologyNeurologyInfectious Diseases
Modalities: Monoclonal antibodiesSmall molecule drugsAntibody-drug conjugates (ADCs)Bispecific antibodiesPolypeptide drugsNucleotide drugs
Industry: Biotech

Beyond the preview

Go deeper on Shanghai Juntuo Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Juntuo Biosciences.

Explore the full profile